Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

Jennifer P. Habashi; Daniel P. Judge; Tammy M. Holm; Ronald D. Cohn; Bart L. Loeys; Timothy K. Cooper; Loretha Myers; Erin C. Klein; Guosheng Liu; Carla Calvi; Megan Podowski; Enid R. Neptune; Marc K. Halushka; Djahida Bedja; Kathleen Gabrielson; Daniel B. Rifkin; Luca Carta; Francesco Ramirez; David L. Huso; Harry C. Dietz

doi:10.1126/science.1124287

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

Jennifer P. Habashi, Daniel P. Judge, Tammy M. Holm, Ronald D. Cohn, Bart L. Loeys, Timothy K. Cooper, Loretha Myers, Erin C. Klein, Guosheng Liu, Carla Calvi, Megan Podowski, Enid R. Neptune, Marc K. Halushka, Djahida Bedja, Kathleen Gabrielson, Daniel B. Rifkin, Luca Carta, Francesco Ramirez, David L. Huso, Harry C. Dietz

Department of Comparative Medicine

Research output: Contribution to journal › Article › peer-review

1445 Scopus citations

Abstract

Aortic aneurysm and dissection are manifestations of Marfan syndrome (MFS), a disorder caused by mutations in the gene that encodes fibrillin-1. Selected manifestations of MFS reflect excessive signaling by the transforming growth factor-β (TGF-β) family of cytokines. We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-β signaling and can be prevented by TGF-β antagonists such as TGF-β-neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. AT1 antagonism also partially reversed noncardiovascular manifestations of MFS, including impaired alveolar septation. These data suggest that losartan, a drug already in clinical use for hypertension, merits investigation as a therapeutic strategy for patients with MFS and has the potential to prevent the major life-threatening manifestation of this disorder.

Original language	English (US)
Pages (from-to)	117-121
Number of pages	5
Journal	Science
Volume	312
Issue number	5770
DOIs	https://doi.org/10.1126/science.1124287
State	Published - Apr 7 2006

All Science Journal Classification (ASJC) codes

General

Access to Document

10.1126/science.1124287

Cite this

Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., Podowski, M., Neptune, E. R., Halushka, M. K., Bedja, D., Gabrielson, K., Rifkin, D. B., Carta, L., Ramirez, F., Huso, D. L., & Dietz, H. C. (2006). Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 312(5770), 117-121. https://doi.org/10.1126/science.1124287

@article{47d44967bcd24e2a9f77060252e7b54d,

title = "Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome",

abstract = "Aortic aneurysm and dissection are manifestations of Marfan syndrome (MFS), a disorder caused by mutations in the gene that encodes fibrillin-1. Selected manifestations of MFS reflect excessive signaling by the transforming growth factor-β (TGF-β) family of cytokines. We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-β signaling and can be prevented by TGF-β antagonists such as TGF-β-neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. AT1 antagonism also partially reversed noncardiovascular manifestations of MFS, including impaired alveolar septation. These data suggest that losartan, a drug already in clinical use for hypertension, merits investigation as a therapeutic strategy for patients with MFS and has the potential to prevent the major life-threatening manifestation of this disorder.",

author = "Habashi, {Jennifer P.} and Judge, {Daniel P.} and Holm, {Tammy M.} and Cohn, {Ronald D.} and Loeys, {Bart L.} and Cooper, {Timothy K.} and Loretha Myers and Klein, {Erin C.} and Guosheng Liu and Carla Calvi and Megan Podowski and Neptune, {Enid R.} and Halushka, {Marc K.} and Djahida Bedja and Kathleen Gabrielson and Rifkin, {Daniel B.} and Luca Carta and Francesco Ramirez and Huso, {David L.} and Dietz, {Harry C.}",

year = "2006",

month = apr,

day = "7",

doi = "10.1126/science.1124287",

language = "English (US)",

volume = "312",

pages = "117--121",

journal = "Science",

issn = "0036-8075",

publisher = "American Association for the Advancement of Science",

number = "5770",

}

Habashi, JP, Judge, DP, Holm, TM, Cohn, RD, Loeys, BL, Cooper, TK, Myers, L, Klein, EC, Liu, G, Calvi, C, Podowski, M, Neptune, ER, Halushka, MK, Bedja, D, Gabrielson, K, Rifkin, DB, Carta, L, Ramirez, F, Huso, DL & Dietz, HC 2006, 'Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome', Science, vol. 312, no. 5770, pp. 117-121. https://doi.org/10.1126/science.1124287

TY - JOUR

T1 - Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

AU - Habashi, Jennifer P.

AU - Judge, Daniel P.

AU - Holm, Tammy M.

AU - Cohn, Ronald D.

AU - Loeys, Bart L.

AU - Cooper, Timothy K.

AU - Myers, Loretha

AU - Klein, Erin C.

AU - Liu, Guosheng

AU - Calvi, Carla

AU - Podowski, Megan

AU - Neptune, Enid R.

AU - Halushka, Marc K.

AU - Bedja, Djahida

AU - Gabrielson, Kathleen

AU - Rifkin, Daniel B.

AU - Carta, Luca

AU - Ramirez, Francesco

AU - Huso, David L.

AU - Dietz, Harry C.

PY - 2006/4/7

Y1 - 2006/4/7

N2 - Aortic aneurysm and dissection are manifestations of Marfan syndrome (MFS), a disorder caused by mutations in the gene that encodes fibrillin-1. Selected manifestations of MFS reflect excessive signaling by the transforming growth factor-β (TGF-β) family of cytokines. We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-β signaling and can be prevented by TGF-β antagonists such as TGF-β-neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. AT1 antagonism also partially reversed noncardiovascular manifestations of MFS, including impaired alveolar septation. These data suggest that losartan, a drug already in clinical use for hypertension, merits investigation as a therapeutic strategy for patients with MFS and has the potential to prevent the major life-threatening manifestation of this disorder.

AB - Aortic aneurysm and dissection are manifestations of Marfan syndrome (MFS), a disorder caused by mutations in the gene that encodes fibrillin-1. Selected manifestations of MFS reflect excessive signaling by the transforming growth factor-β (TGF-β) family of cytokines. We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-β signaling and can be prevented by TGF-β antagonists such as TGF-β-neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. AT1 antagonism also partially reversed noncardiovascular manifestations of MFS, including impaired alveolar septation. These data suggest that losartan, a drug already in clinical use for hypertension, merits investigation as a therapeutic strategy for patients with MFS and has the potential to prevent the major life-threatening manifestation of this disorder.

UR - http://www.scopus.com/inward/record.url?scp=33645672459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645672459&partnerID=8YFLogxK

U2 - 10.1126/science.1124287

DO - 10.1126/science.1124287

M3 - Article

C2 - 16601194

AN - SCOPUS:33645672459

SN - 0036-8075

VL - 312

SP - 117

EP - 121

JO - Science

JF - Science

IS - 5770

ER -

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this